Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
- None.
- None.
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in
Management will also be available for one-on-one meetings with investors at the conference. Investors who are interested in meeting are encouraged to reach out to their representative at Canaccord Genuity.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test is performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device. EsoGuard and EsoCheck are the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-present-at-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-301975934.html
SOURCE Lucid Diagnostics
FAQ
What is the name of the company mentioned in the press release?
Who is the Chairman and CEO of Lucid Diagnostics Inc.?
When and where will the presentation take place?
Will management be available for meetings with investors at the conference?
How can investors schedule a meeting with Lucid Diagnostics Inc.?
